Search results
Results From The WOW.Com Content Network
Reconstituted ceftriaxone injection solutions are light yellow- to amber-colored depending on how long the solution had been reconstituted, the concentration of ceftriaxone in the solution, and the diluent used. [8] To reduce pain with intramuscular injections, ceftriaxone may be reconstituted with lidocaine. [40]
Injector pens remove some of the complications of syringes by allowing the pen to be "pushed" against the skin at a 90-degree angle (removing the need to inject at a proper angle as is the case with syringes), as well as by replacing a long, thin plunger of a syringe with a simple button which is depressed and held to inject the dose. [2]
Use of 1% tetracycline ointment, 0.5% erythromycin ointment, or 1-2% silver nitrate solution (Credé's method) into the eyes of babies immediately after birth. [6] Single injection of ceftriaxone IM or IV should be given to infants born to mothers with untreated gonococcal infection.
Intraperitoneal injection or IP injection is the injection of a substance into the peritoneum (body cavity). It is more often applied to non-human animals than to humans. In general, it is preferred when large amounts of blood replacement fluids are needed or when low blood pressure or other problems prevent the use of a suitable blood vessel for intravenous injection.
The two techniques Travell described are the injection of a local anesthetic and the mechanical use of a hypodermic needle without injecting a solution. [8] Travell preferred a, 1.5-in hypodermic needle for trigger point therapy and used this needle for both injection therapy and dry needling. Travell never used an acupuncture needle.
Overdoses of lidocaine may result from excessive administration by topical or parenteral routes, accidental oral ingestion of topical preparations by children (who are more susceptible to overdose), accidental intravenous (rather than subcutaneous, intrathecal, or paracervical) injection, or from prolonged use of subcutaneous infiltration ...
The Phase 2/3 pivotal confirmatory trial of OCU410ST will randomize 51 subjects, 34 of whom will receive a single subretinal, 200-microliter injection of OCU410ST at a concentration of 1.5 times ...
Bacitracin is a polypeptide antibiotic derived from a bacterium, Bacillus subtilis, and acts against bacteria through the inhibition of cell wall synthesis. [6] It does this by inhibiting the removal of phosphate from lipid compounds, thus deactivating its function to transport peptidoglycan; the main component of bacterial cell membranes, to the microbial cell wall.